PMID- 23826581
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130705
LR  - 20211021
IS  - 2287-979X (Print)
IS  - 2288-0011 (Electronic)
IS  - 2287-979X (Linking)
VI  - 48
IP  - 2
DP  - 2013 Jun
TI  - CD163 and c-Met expression in the lymph node and the correlations between 
      elevated levels of serum free light chain and the different clinicopathological 
      parameters of advanced classical Hodgkin's lymphoma.
PG  - 121-7
LID - 10.5045/br.2013.48.2.121 [doi]
AB  - BACKGROUND: Advances in the understanding of Hodgkin's lymphoma (HL) show various 
      functions of infiltrating immune cells and cytokines in relation to clinical 
      outcomes. The expression of CD163 and c-Met has been suggested to have a role in 
      lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and 
      serum free light chain (sFLC) in relation to the clinicopathological features of 
      patients with advanced classical HL (cHL). METHODS: We assessed the expression of 
      CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph 
      node biopsy sections and the levels of pretreatment sFLC were estimated using 
      ELISA. RESULTS: High CD163 expression correlated with increased age, B symptoms, 
      International Prognostic Score (IPS) >/=3, mixed cellularity subtype, and low 
      response to treatment. Further, high c-Met expression correlated with increased 
      age at diagnosis, leukocytosis, B symptoms, and lower chance to achieve complete 
      remission. The sFLC levels correlated with increased age at diagnosis, 
      lymphopenia, IPS >/=3, B symptoms, and lower complete remission rates. CONCLUSION: 
      In advanced cHL, increased expression of CD163 and c-Met showed a significant 
      association with adverse prognostic parameters and poor response to treatment. 
      Pretreatment high sFLC level also correlated with poor risk factors, suggesting 
      its use as a candidate prognostic marker. A comprehensive approach for prognostic 
      markers might represent a step towards developing a tailored therapeutic approach 
      for HL.
FAU - Bedewy, Magdy
AU  - Bedewy M
AD  - Military Medical Academy, Cairo, Egypt.
FAU - El-Maghraby, Shereen
AU  - El-Maghraby S
FAU - Bedewy, Ahmed
AU  - Bedewy A
LA  - eng
PT  - Journal Article
DEP - 20130625
PL  - Switzerland
TA  - Blood Res
JT  - Blood research
JID - 101605247
PMC - PMC3698397
OTO - NOTNLM
OT  - CD163
OT  - Free light chain
OT  - Hodgkin
OT  - c-Met
COIS- No potential conflicts of interest relevant to this article were reported.
EDAT- 2013/07/05 06:00
MHDA- 2013/07/05 06:01
PMCR- 2013/06/01
CRDT- 2013/07/05 06:00
PHST- 2013/01/23 00:00 [received]
PHST- 2013/05/17 00:00 [accepted]
PHST- 2013/07/05 06:00 [entrez]
PHST- 2013/07/05 06:00 [pubmed]
PHST- 2013/07/05 06:01 [medline]
PHST- 2013/06/01 00:00 [pmc-release]
AID - 10.5045/br.2013.48.2.121 [doi]
PST - ppublish
SO  - Blood Res. 2013 Jun;48(2):121-7. doi: 10.5045/br.2013.48.2.121. Epub 2013 Jun 25.